<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/216D191F-5CE8-47C1-91A9-2A5392E83A8A"><gtr:id>216D191F-5CE8-47C1-91A9-2A5392E83A8A</gtr:id><gtr:name>Ludwig Boltzmann Society</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1"><gtr:id>0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1</gtr:id><gtr:name>University of Massachusetts (UMass)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0178BF67-3630-48EE-B360-6389F6D35308"><gtr:id>0178BF67-3630-48EE-B360-6389F6D35308</gtr:id><gtr:name>Paracelsus Medical University Salzburg</gtr:name><gtr:address><gtr:line1>Strubergasse 21</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CE589CCE-4366-4CEE-883A-CC75CF6E58D8"><gtr:id>CE589CCE-4366-4CEE-883A-CC75CF6E58D8</gtr:id><gtr:name>Cincinnati Children's Hospital Medical Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5DF5258-6FC1-4F92-928B-2E970FF914D4"><gtr:id>D5DF5258-6FC1-4F92-928B-2E970FF914D4</gtr:id><gtr:name>The University of Iowa</gtr:name><gtr:address><gtr:line1>203 Van Allen Hall</gtr:line1><gtr:line4>Iowa City</gtr:line4><gtr:line5>IA 52242-1479</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8B7C8B1B-87E1-482C-B0C7-5C9D4EEE8355"><gtr:id>8B7C8B1B-87E1-482C-B0C7-5C9D4EEE8355</gtr:id><gtr:name>European Cooperation in Science and Technology (COST)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/91C308E2-1EBA-4CC1-8183-0371468DE15E"><gtr:id>91C308E2-1EBA-4CC1-8183-0371468DE15E</gtr:id><gtr:name>Wayne State University</gtr:name><gtr:address><gtr:line1>Detroit</gtr:line1><gtr:line2>Michigan</gtr:line2><gtr:line3>MI 48202</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AD4854E1-71AF-4687-93A9-5F05968D34DB"><gtr:id>AD4854E1-71AF-4687-93A9-5F05968D34DB</gtr:id><gtr:name>University of Pisa</gtr:name><gtr:address><gtr:line1>University of Pisa</gtr:line1><gtr:line2>Lungarno Pacinotti 43</gtr:line2><gtr:line4>Pisa</gtr:line4><gtr:postCode>I 56126</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:department>Clinical and Experimental Sciences</gtr:department><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/216D191F-5CE8-47C1-91A9-2A5392E83A8A"><gtr:id>216D191F-5CE8-47C1-91A9-2A5392E83A8A</gtr:id><gtr:name>Ludwig Boltzmann Society</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1"><gtr:id>0A32DF0B-F2C5-42D5-A74A-32E1FD6B47D1</gtr:id><gtr:name>University of Massachusetts (UMass)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0178BF67-3630-48EE-B360-6389F6D35308"><gtr:id>0178BF67-3630-48EE-B360-6389F6D35308</gtr:id><gtr:name>Paracelsus Medical University Salzburg</gtr:name><gtr:address><gtr:line1>Strubergasse 21</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CE589CCE-4366-4CEE-883A-CC75CF6E58D8"><gtr:id>CE589CCE-4366-4CEE-883A-CC75CF6E58D8</gtr:id><gtr:name>Cincinnati Children's Hospital Medical Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5DF5258-6FC1-4F92-928B-2E970FF914D4"><gtr:id>D5DF5258-6FC1-4F92-928B-2E970FF914D4</gtr:id><gtr:name>The University of Iowa</gtr:name><gtr:address><gtr:line1>203 Van Allen Hall</gtr:line1><gtr:line4>Iowa City</gtr:line4><gtr:line5>IA 52242-1479</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8B7C8B1B-87E1-482C-B0C7-5C9D4EEE8355"><gtr:id>8B7C8B1B-87E1-482C-B0C7-5C9D4EEE8355</gtr:id><gtr:name>European Cooperation in Science and Technology (COST)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/91C308E2-1EBA-4CC1-8183-0371468DE15E"><gtr:id>91C308E2-1EBA-4CC1-8183-0371468DE15E</gtr:id><gtr:name>Wayne State University</gtr:name><gtr:address><gtr:line1>Detroit</gtr:line1><gtr:line2>Michigan</gtr:line2><gtr:line3>MI 48202</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AD4854E1-71AF-4687-93A9-5F05968D34DB"><gtr:id>AD4854E1-71AF-4687-93A9-5F05968D34DB</gtr:id><gtr:name>University of Pisa</gtr:name><gtr:address><gtr:line1>University of Pisa</gtr:line1><gtr:line2>Lungarno Pacinotti 43</gtr:line2><gtr:line4>Pisa</gtr:line4><gtr:postCode>I 56126</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/63CD896B-E0AF-4D6B-8BCF-58BA2160323C"><gtr:id>63CD896B-E0AF-4D6B-8BCF-58BA2160323C</gtr:id><gtr:firstName>Hans</gtr:firstName><gtr:otherNames>Michael</gtr:otherNames><gtr:surname>Haitchi</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0802804"><gtr:id>CBB42C50-552A-4CEE-856F-1B47DA9993DF</gtr:id><gtr:title>ADAM33 gene and environment interactions in developing lungs and their involvement in the early life origin of asthma</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0802804</gtr:grantReference><gtr:abstractText>Asthma is a common disease affecting both adults and children. It causes wheeziness, chest
tightness and cough and is often triggered by exposure to allergens (eg. dust or animal fur). As a
result, the airways contract too much and too easily, limiting airflow into the lung. Asthma tends to
run in families suggesting there are ?asthma? genes. ADAM33 is such a gene where small changes
have been found in people with asthma and in young children at risk of asthma. It is found in
specialized airway ?smooth muscle? cells (ASMCs) that cause airway ?twitchiness? in asthma and it is
released in fluid that is present in the airways of asthmatic patients. In baby lungs, I have found
that ADAM33 occurs in stem cells that give rise to ASMCs. Therefore, the objectives of my research
are to study the role of ADAM33 in airway development and to understand whether release of
ADAM33 can give rise to abnormal ASMC development that might lead to asthma. I will also
investigate whether, and how maternal allergy, a factor that predisposes babies for asthma, affects
ADAM33 in ASMC. These studies should help devise new treatments for asthma close to the origin of
the disease.</gtr:abstractText><gtr:technicalSummary>Aims: A Disintegrin And Metalloprotease (ADAM)33 is a susceptibility gene associated with asthma,
bronchial hyperresponsiveness (BHR) and reduced lung function in young children. High levels of a
55 kDa soluble fragment of ADAM33 (sADAM33) have been found in bronchoalveolar lavage fluid
(BALF) of asthmatic subjects where levels correlate with reduced lung function. To investigate the
early life contribution of ADAM33 to asthma pathogenesis, I have found that ADAM33 expression
increases when spontaneous peristaltic contractions of the airways commence in utero and when the
lungs inflate post partum. Using human embryonic lung explants, I have found that recombinant
sADAM33 enhances smooth muscle development, identifying a novel function for sADAM33.
Furthermore, in genetically susceptible A/J mice, I have found that maternal allergy suppresses
ADAM33 expression in the offspring and that this is associated with reduced airways smooth muscle
and increased airway reactivity. This suggests a gene-environment interaction that leads to altered
airway structure and function. Based on these observations I now wish to test the hypothesis that
ADAM33 influences bronchial smooth muscle growth to affect airway development and that
environmental factors in utero interact with ADAM33 leading to a vulnerable airway structure that
predisposes to the development of asthma in childhood or later in life.
Objectives &amp;amp; Methods:
To test my hypothesis I will address these questions:
1. What is the effect of maternal allergy on airway development and its consequences on airway
structure and function in juvenile mice? This will involve in depth imaging of the airway structure
and correlation with airway mechanics and function. To assess the potential for gene-environment
interactions, the studies will use both A/J (BHR1/ADAM33 positive) and BALB/c (BHR1 negative)
mice.
2. Does release of sADAM33 affect smooth muscle growth, airway development and post natal
airway function? This will be assessed using a conditional transgenic mouse expressing sADAM33;
the consequences of altered structure on airway function will be assessed.
3. Do the ADAM33 mechanisms identified in murine lung development occur in developing human
lungs? This will be assessed using gain or loss of function approaches applied to human embryonic
lung explants. I will determine whether sADAM33 is detectable in vivo in amniotic fluid from allergic
mothers and BALF from paediatric asthma patients.
Scientific opportunities: These studies will provide new insight into gene-environment
interactions in utero and their effect on the early origins of asthma. This might lead to novel
prevention and intervention strategies early in life.</gtr:technicalSummary><gtr:fund><gtr:end>2014-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1035126</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Cooperation in Science and Technology (COST)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>COST Action BM1201</gtr:description><gtr:id>DB71624B-5188-4FD9-81C0-0D9E195EED4B</gtr:id><gtr:impact>Following the 1st COST meeting a research collaboration has been established with a research group in Graz, Austria. 
From this collaboration a first manuscript was published in Am J Physiol Lung Cell Mol Physiol. 2015 May 15;308(10):L1002-13 and a second manuscript has been submitted to Antioxidants &amp;amp; Redox Signaling in 2017.
Although the COST Action BM1201 had its final meeting in November 2016 I have also established collaborations with Professors. Seal Salani &amp;amp; Andrew Bush from Imperial College London, who were both members of COST BM1201 and are now collaborators on the MRF/AUK 2015-322 grant.</gtr:impact><gtr:outcomeId>LL3V6bpxy2N-1</gtr:outcomeId><gtr:partnerContribution>COST Action provided a travel support for the first COST conference and enable me to meet scientists in the same field as my MRC funded research interest. 
COST will also provide financial support for short term collaborative visits between different European countries.
My postdoctoral research on the MRF/AUK grant submitted and abstract and was invited for an oral presentation at the final Annual Meeting of COST BM 1201: Early Origins of Chronic Lung Disease: &amp;quot;The end of the beginning&amp;quot;. Athens, Greece, 3-4th of November 2016.</gtr:partnerContribution><gtr:piContribution>As a member of COST Action BM1201 I have been invited to give a talk about my research on the role of ADAM33 in lung development at the first COST Conference in Munich, Germany from the 13-15 June 2013. This was closely related to the COST Action about the Developmental Origins of Chronic Lung Disease.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Paracelsus Private Medical University of Salzburg (Paracelsus Medizinische Privatuniversit?t PMU)</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>ADAM33 in COPD and Lung Tumours</gtr:description><gtr:id>F813731E-4FAD-4AA9-B9C6-45057A143B10</gtr:id><gtr:impact>Results from this work have been presented as oral presentation at the European Respiratory Society (ERS) Congress in Viennna, Austria in 2012.
A manuscript is in preparation for publication in 2017.</gtr:impact><gtr:outcomeId>545768d7cef540.85609229-1</gtr:outcomeId><gtr:partnerContribution>Our partner was fully in involved in writing a research protocol and submitting this to their local ethical commission.
Furthermore, they provided and sent research samples to Southampton for further analysis.
A part-time PhD student at the PMU spend several month in Southampton as part of the research project and for her PhD in 2010, 2013, 2016.
The PhD student has submitted her thesis in February 2017 and is awaiting her viva.</gtr:partnerContribution><gtr:piContribution>We help to set up a clinical study in Salzburg writing a research protocol and providing clinical study protocols and forms. We were closely involved in the ethical approval application in Salzburg.
We also provided research reagents and plastics which were sent to Salzburg for sample collection. Biological samples were received and processed further in Southampton.
A PhD student from Salzburg has spent several 1 to 3 months periods in Southampton analyse the samples from Austria.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Novel oligonucleotides and conjugates for ADAM33 asthma research and therapy</gtr:description><gtr:id>2BF8742B-6281-4B63-B3BE-B99EDBB0448E</gtr:id><gtr:impact>Our work has been presented at national and international conferences in abstract form.
We have also prepared a manuscript for submission in 2016.</gtr:impact><gtr:outcomeId>54575a2a1c6538.21304983-1</gtr:outcomeId><gtr:partnerContribution>The partner developed and synthesised novel oligonucleotides, which they tested in biological assays in their and our laboratory.</gtr:partnerContribution><gtr:piContribution>We provided cell lines and sequences for ADAM33 siRNA, antibodies, RTqPCR reagents and also space to do experiments in our laboratory.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Massachusetts (UMass)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>University of Massachusetts Medical School</gtr:department><gtr:description>Inhibition of ADAM33 by advanced oligonucleotides to reverse pathological airway remodeling in asthma</gtr:description><gtr:id>64ADFE48-385A-4C62-A987-316C1C306BB5</gtr:id><gtr:impact>We have recently submitted a grant application to the American Asthma Foundation Research Program for the 2016 AAF Scholar Award in December 2016, which got ranked very highly, but AAF was not able to find this work. I was named as co-inestitgator. The aim was use our ADAM33 mouse models from here in Southampton to test some of the novel oligonucleotides that will be generated in the US.
We are in the process of putting a patent application together for these new oligonucleotide compounds in 2017. This is currently under review by the Office of Technology Management, University of Massachusetts Medical School and a patent attorney.
Furthermore, a manuscript is has been submitted to Molecular Therapy - Nucleic Acids in March 2017.</gtr:impact><gtr:outcomeId>56d830e6310c82.52314070-1</gtr:outcomeId><gtr:partnerContribution>Jon has made some novel oligonucleotides, which we have tested in different cell lines and are strong inhibitors of human and mouse ADAM33.
We will try to use these also in our ADAM33 mouse models in adult mice and very early in life.</gtr:partnerContribution><gtr:piContribution>This is a collaboration between Associate Professor Dr. Jonathan Watts and his group, which started a few years ago when he was working at the University of Southampton. In 2015 he moved to the University of Massachusetts Medical School.
I have provide the initial idea to develop novel oligonucleotides for inhibition of the asthma gene ADAM33, which was based on preliminary data from siRNA experiments from my PhD work.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Natural and Environmental Sciences</gtr:department><gtr:description>Discovery of novel ADAM33-MP inhbitors</gtr:description><gtr:id>4258191B-5470-469D-9975-CAA90782BC14</gtr:id><gtr:impact>This has resulted in the discovery of several very promising compounds. We have signed confidential and material exchange agreement with MRC-Technology and industry that provided with access to compound libraries. This enabled us to test the most promising compounds in our computational modelling softwares, order the most promising compounds and test them in our FRET peptide assays.
The next step is to get the crystal structure of ADAM33 with and without the compounds and test the compounds in our transgenic ADAM33 mouse models.
This collaboration has resulted in further grant support by the Asthma Allergy &amp;amp; Inflammation Charity in 2013.
We have also submitted a preliminary application for a Wellcome Trust Seeding Drug Discovery scheme in Nov 2014 which was not successful.
We have started discussion with industry to take this exciting development of ADAM33-MP inhibitors further in 2015/2016.</gtr:impact><gtr:outcomeId>ZWWH8mqyNSr-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators from the department of chemistry have used the Zinc data base and different docking softwares to find and design novel and specific ADAM33 inhibitors.</gtr:partnerContribution><gtr:piContribution>I sought the collaboration with the department of chemistry with the aim to us the Zinc data base and computational modelling to find novel inhibitors for the metalloprotease of ADAM33 using the existent crystal structure. I then test novel compounds that arose from these searches in our FRET-based peptide cleavage essay for screening to find the most promising inhibitors and then performing IC50 assays.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wayne State University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Family Medicine and Public Health Sciences</gtr:department><gtr:description>Maternal allergen exposure mouse model, Detroit, US</gtr:description><gtr:id>041D78D1-917D-432C-BC39-F0E410F9432D</gtr:id><gtr:impact>Manuscript is in preparation for submission to Clinical and Experimental Allergy in 2017.</gtr:impact><gtr:outcomeId>Wvp5HsvqJmn-1</gtr:outcomeId><gtr:partnerContribution>The collaborator Professor David Bassett in Detroit helped in setting up a maternal allergen exposure mouse model and performed experiments on these mice and their offspring. These included performing non-invasive and invasive lung function measurements and collecting and shipping of samples to the UK.
Our laboratory is in the process of receiving lung function and animal exposure equipment on loan from the laboratory in the US which will be additional to our own small animal challenge and lung function laboratory in the UK.
In 2014 and 2016 we have received equipment from the lab in Detroit for doing non-invasive lung function measurements (Buxco System for Penh measurements). This has allowed us to expand our small animal lung function laboratory at the University of Southampton in 2017.
Professor Basset has come for regular meeting to Southampton in 2016 and 2017 and has given us helpful advice in doing our allergen challenge models as well as performing lung function analysis in our ADAM33 mouse models.</gtr:partnerContribution><gtr:piContribution>I personally spent some time in the lab in Detroit and helped to plan and set up the experiments and helped with the use of invasive lung function methods. Furthermore, samples send from Detroit will be further analysed in Southampton, UK.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pisa</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Clinical Immunology/Rheumatology Units</gtr:department><gtr:description>Purification of recombinant soluble ADAM33 and functional studies</gtr:description><gtr:id>59E150CF-9BC6-4D53-95D3-8C601F742A3F</gtr:id><gtr:impact>This collaboration has allowed us to scale up our purification of soluble ADAM33, which we use in our ex vivo culture models and also for screen novel compounds as ADAM33 inhibitors using a FRET assay.
We also use this purified recombinant soluble ADAM33 protein in our FRET assays of samples from our ADAM33 mouse models as part of the MRF/AUK grant.
Work from this collaboration has resulted in an Abstract presentation at European Academy of Allergy and Clinical Immunology (EAACI) Congress in Barcelona in 2015.
A manuscript is presently in preparation for submission in 2017.</gtr:impact><gtr:outcomeId>KjGXT8PC2cA-1</gtr:outcomeId><gtr:partnerContribution>A PhD student from Pisa came over to work for 6 months in our laboratory and purify soluble ADAM33.
Purified soluble ADAM33 has been used for different in vitro and in vivo functional assays.
The partner have set up also a HUVEC tube formation assay which they will use to test some of our novel anti-ADAM33 compounds.
The partner has also set up chic chorioallantoic membrane (CAM) assays as an angiogenesis assay for soluble ADAM33 and our novel small compound inhibitors.</gtr:partnerContribution><gtr:piContribution>We provided the stably transfected insect cells and reagents and apparatus necessary for purification of soluble ADAM33.
Supervision of PhD student from Pisa, Italy.
Provision of purified soluble ADAM33 to the group in Italy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Boltzmann Society</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:department>Ludwig Boltzmann Institute for Lung Vascular Research</gtr:department><gtr:description>ADAM33 in lung vascular research and the role of p22phox in asthma</gtr:description><gtr:id>FD13119F-D5A7-4117-AAC3-547EA2034AAD</gtr:id><gtr:impact>Collaboration as part of COST Action (European Cooperation in Science and Technology) BM1201: Developmental Origins of Chronic Lung Disease.
A manuscript was published describing the expression of ADAM33 in pulmonary fibrosis in Am J Physiol Lung Cell Mol Physiol. 2015 May 15;308(10):L1002-13.

A manuscript describing the role of p22phox in asthma has been submitted to Antioxidants and Redox Signaling is presently under revision in 2017.</gtr:impact><gtr:outcomeId>SftYiJYmCEG-1</gtr:outcomeId><gtr:partnerContribution>Use of recombinant ADAM33 in established lung vascular research models.

Combining our human data with mouse derived data and experiments in Graz.</gtr:partnerContribution><gtr:piContribution>Purification of recombinant ADAM33 protein and provision of protein for in vitro studies as well as ADAM33 knock out mouse in future for in vivo studies.
Use of expertise about ADAM33 for experiments and interpretation of data from human samples of lung fibrosis.

RTqPCR experiments to study expression of p22phox in bronchial samples from patients with asthma and healthy control subjects and analysis of the data.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Iowa</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Internal Medicine</gtr:department><gtr:description>Reactive Oxgen Species in Asthma</gtr:description><gtr:id>F4C40917-5154-4582-A847-2EEAC985890B</gtr:id><gtr:impact>This collaboration resulted in a joint publication PMID 23884469.</gtr:impact><gtr:outcomeId>aqb9qvyfHVq-1</gtr:outcomeId><gtr:partnerContribution>This collaboration gave us access to a new field in asthma research and we might use some of the tools developed in Iowa for our research.</gtr:partnerContribution><gtr:piContribution>This collaboration has allowed me as a MRC clinician scientist to use our samples from patients for new experiments in order to study novel mechanisms in the pathogenesis of asthma that are related to my research interest.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cincinnati Children's Hospital Medical Center</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Section of Neonatology, Perinatal and Pulmonary Biology</gtr:department><gtr:description>Transgenic mouse models in respiratory research Cincinnati, US</gtr:description><gtr:id>412CC630-A997-40E0-B795-C73A47F4668F</gtr:id><gtr:impact>The access to samples and data from the University of Southampton resulted in joint publications PMID: 21562130 &amp;amp; PMID: 21642246. Furthermore, I was able to apply my expertise in Micro-CT to samples in CCHMC and to further develop a contrast enhancing method for Micro-CTs resulting in another joint publication PMID: 21803035.
As part of my MRC-CRF I was able to generate two transgenic ADAM33 mouse lines and regenerate an ADAM33-null mouse which will now be available in Southampton.
We have also generated novel micro-array data from cystic fibrosis and healthy primary paediatric epithelial cell cultures which will enable us to write joint grant applications. Part of this work has been submitted as scientific abstract at the American Thoracic Society (ATS) meeting 2012.
The access to an IL-13 transgenic mouse model has resulted submission of two more scientific abstracts at the ATS meeting 2012.
Further work done in collaboration on SPDEF in Cincinnati resulted in the joint publication PMID 23012424.
First results from ADAM33 work has been submitted and presented as scientific abstract to American Thoracic Society (ATS) meeting in San Diego, USA in 2014 and European Respiratory Society (ERS) Congress in Munich, Germany in 2014.
In 2014, RNA samples for transgenic mouse lungs have been sent to Cincinnati Children's Hospital Research Centre (CCHMC) for next generation sequencing and bioinformatic analysis.
In 2015 my PhD student spent 3 week bioinformatics training using our NGS data from the transgenic ADAM33 mice in CCHMC.
We will also send more samples from the ADAM33 knock out mouse for NGS to CCHMC in 2016.
As part of the recently awarded MRF-AUK grant (2015) we will do more NGS together with CCHMC and a PhD student will go for further training in bioinformatics and lung biology to CCHMC in 2017/2018.
In 2016 we published our data from human samples and our ADAM33 mouse models in JCI Insight PMID: 27489884.
This publication has made a significant contribution to our understanding how soluble ADAM33 initiates airway remodelling, which promotes susceptibility for allergic asthma in early life. The publication has attracted wide attention by national and international media and the scientific community.</gtr:impact><gtr:outcomeId>eBpg4WBVjQQ-1</gtr:outcomeId><gtr:partnerContribution>access to equipment &amp;amp; facilities, training of staff, significant intellectual input into research.</gtr:partnerContribution><gtr:piContribution>access to samples and data, training of staff, significant intellectual &amp;amp; practical input into collaborative research.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Natural and Environmental Sciences</gtr:department><gtr:description>Purification of recombinant ADAM33 &amp;amp; crystal structure of ADAM33-MP inhibitor complexes</gtr:description><gtr:id>B587F122-9B96-4C94-B1CC-61C29DDBAACC</gtr:id><gtr:impact>We have now already purified protein in large scale that we can use for our FRET peptide based assays and protein has also been send to our Italian collaborators who use the protein in angiogenesis based assays.
In 2014 we have now also established stably transfected insect cells not only with human ADMA33-MP-Pro (active and mutated inactive) but also for the mouse ADAM33 (active and mutated inactive), which we have been using for purification of recombinant human and mouse ADAM33.
In 2015 we have used the recombinant ADAM33 protein in cell culture experiments and will use more of the protein in 2016.
We have now a working protocol for the purification and will try to increase our yield for crystallography in 2016.</gtr:impact><gtr:outcomeId>WgDhrYdU68y-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators help with the purification of ADAM33-MP which will provide enough protein for crystal structure analysis.</gtr:partnerContribution><gtr:piContribution>Our team provides the conditional medium from ADAM33-MP stably tranfected insect cells for purification of ADAM33-MP at the Institute for Life Sciences at the University of Southampton. We also tested the compounds discovered in collaboration with chemistry to find the most promising ones that will be used to get the ADAM33-MP complex crystal structure.
We recently developed a collaboration in order to scale up our protein purification with the protein purification group at Cancer Research at the University of Southampton (Aug 2013).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Gero's IMR: ADAM33-Gen k?nnte Asthma stoppen</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8BEBC84D-7202-408D-B8FB-B8C10023BA84</gtr:id><gtr:impact>This was a full report in the Gerontological-Economic Research Organisation's report of the &amp;quot;GERO's Internationaler Medizin-Report&amp;quot; Number 11, Nov 2016 in response to the press release by the University of Southampton in connection with our publication in The Journal of Clinical Investigation - Insight with the title: Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life in 2016.</gtr:impact><gtr:outcomeId>58c964eb878ec4.88119333</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://gero.org/5/gero?&amp;wslanguage=en</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release: Stop the rogue ADAM gene and you stop asthma.</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3D27F110-1B10-44EF-BFFC-D45B71F27022</gtr:id><gtr:impact>This press release was send out by the University of Southampton in connection with our publication in The Journal of Clinical Investigation - Insight with the title: Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life in 2016.
This publication has made a significant contribution to our understanding how soluble ADAM33 initiates airway remodelling, which promotes susceptibility for allergic asthma in early life and the press release has attracted wide attention by national and international media and the scientific community (Australia, Austria, Belgium, India, Ireland, USA, UK, ...).
The Article was covered over 100 times in the media: in local newspapers (southern Daily Echo) and all national newspapers (The Independent, The Daily Telegraph, The Daily Mirror, The Sun, ...)in the UK and even in international newspapers (Business Standard India, ...). Additionally it was covered by engagement focused websites, bogs and social media channels, local radio and TV stations and national radio stations.</gtr:impact><gtr:outcomeId>58c94d13da29c0.00402721</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.southampton.ac.uk/news/2016/07/adam-33-gene.page</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dani King dinner 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>64BF9FBA-5D07-4852-9203-FB874029ACFF</gtr:id><gtr:impact>About hundred people attended this evening programme together with dinner with our Olympian gold medalist Dani King on the 11th April 2013. The dinner was sponsored by DC Employment Solicitors and an auction was conducted by BBC's Graham Barton to raise funds for the AAIR charity. I was invited to give a short talk about my MRC and AAIR charity funded asthma research in Southampton. After dinner this gave me the opportunity to interact with many guests of the evening and to answer many asthma and research related questions.

The dinner guests generously participated in the auction for the benefit of the AAIR charity. Some of the guests made enquires how they could get involved in asthma research, such as volunteers for asthma research.</gtr:impact><gtr:outcomeId>UBCezqcuP6V</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:url>http://www.aaircharity.org</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New study to assess why 'rogue gene' causes asthma in early life</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CF84228D-E67B-4A98-8ABD-604A96CA8916</gtr:id><gtr:impact>The press release by the University of Southampton about our new Medical Research Foundation/Asthma UK study with the title &amp;quot;The impact of pre- and perinatal ADAM33 induced airway remodeling on sensitivity to environmental challenges and the early life development of asthma&amp;quot; was picked up by MedicalXpress as part of Science X? that is a leading web-based science, research and technology news service.</gtr:impact><gtr:outcomeId>58c94bea173131.89337374</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://medicalxpress.com/news/2016-03-rogue-gene-asthma-early-life.html</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Online interview: Loss of ADAM33 suppresses features of asthma, suggesting targeting ADAM33 as a potential new asthma therapy</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D3186FEE-B359-4656-83F2-AE2472FDB92E</gtr:id><gtr:impact>This was a online interview with Medical Research.com, an international web-based Medical News platform, in response to the press release by the University of Southampton in connection with our publication in The Journal of Clinical Investigation - Insight with the title: Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life in 2016.</gtr:impact><gtr:outcomeId>58c95547306d02.15969800</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>https://medicalresearch.com/author-interviews/loss-adam33-suppresses-features-asthma-suggesting-targeting-adam33-potential-new-asthma-therapy/26487/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>That's Solent TV: Southampton Scientists Discover Potential Way Of Reducing The Symptoms of Asthma</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4B1F193D-64FE-4EE5-BC3D-D42FA23471D0</gtr:id><gtr:impact>This was a filmed and recorded interview for That's Solent TV, a local TV station, in response to the press release by the University of Southampton in connection with our publication in The Journal of Clinical Investigation - Insight with the title: Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life in 2016.</gtr:impact><gtr:outcomeId>58c95292656ac1.61796414</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=Ei7lW-7fRGw</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AAIR charity yearly memorial christmas service</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6F761834-07F3-4375-B3A6-C557880BA4BD</gtr:id><gtr:impact>Between 10 and 30 people attended this memorial service in memory of patients who died off asthma and in support of their families who often support the AAIR charity and our research.
After the service there is always a short reception with minced pies and drinks which enables researchers to engage and interact with the visitors and answer questions about our asthma research.</gtr:impact><gtr:outcomeId>56d83654349b11.14438700</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.aaircharity.org</gtr:url><gtr:year>2013,2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release: New study to assess why 'rogue gene' causes asthma in early life</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>83E8B443-22ED-427D-9861-B796ED4A533A</gtr:id><gtr:impact>This press release about new grant from Medical Research Foundation/Asthma UK with the title: The impact of pre- and perinatal ADAM33 induced airway remodeling on sensitivity to environmental challenges and the early life development of asthma. This was picked up by some local and national media.</gtr:impact><gtr:outcomeId>58c94a6a7637e4.67665733</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.southampton.ac.uk/news/2016/03/rougue-asthma-gene-study.page</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio broadcast: Wave 105: Rogue gene could be key to preventing asthma.</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D5028786-5C87-424E-878B-22BF08501D23</gtr:id><gtr:impact>This was a recorded interview for Radio Wave 105.2, a local radio station, in response to the press release by the University of Southampton in connection with our publication in The Journal of Clinical Investigation - Insight with the title: Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life in 2016.</gtr:impact><gtr:outcomeId>58c9507f7db484.36206828</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.facebook.com/Wave105/posts/1114652868570857</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LifeLab Meet the Scientist Training 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>AF205EEB-E985-4310-92E8-F02BD344FCF0</gtr:id><gtr:impact>*Be able to identify key points of my own Asthma &amp;amp; ADAM33 research, which will generate discussion amongst teenagers
*Be able to communicate my research story effectively to different audiences - with some
appreciation of how to modify for different audiences
*Be able to facilitate a discussion about my research amongst teenagers
*To build up my skills needed for this facilitation - confidence in own communication skills,
questioning skills, listening skills
*To build up confidence in dealing with school students and the different scenarios which might
arise!

I was invited to take part in a public engagement event -lung health funded by NC3Rs and was awarded to highlight our human based models of the airways to the public in our Faculty of Medicine LifeLab on 17th November 2014
This event is 
I was also invited to take part in 'meet the scientist' sessions for school students in our LifeLab in December 2014.</gtr:impact><gtr:outcomeId>54635c55584710.38481635</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.southampton.ac.uk/lifelab</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Live Broadcast: Shaun Doherty Show - Highland Radio in Ireland: ADAM33 and asthma.</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2E57AEE1-233E-4A74-A4F3-D560D2DE9CE7</gtr:id><gtr:impact>This was a live interview at the Shaun Doherty Show at Highland Radio, a local radio station in Irland, in response to the press release by the University of Southampton in connection with our publication in The Journal of Clinical Investigation - Insight with the title: Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life in 2016.</gtr:impact><gtr:outcomeId>58c95158eb1e93.72232865</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.highlandradio.com/shaun-doherty/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AAIR Charity Summer Fair 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>515BEAEB-F7C6-4A7C-BE92-F8F528112393</gtr:id><gtr:impact>Talking about my asthma research (funded by the MRC and AAIR charity) with people from the public sparked questions: some of them related to my asthma research, some of the of clinical nature about themselves or friends or relatives who suffer from asthma. Some people also wanted to find out how they could support our local/regional research.

This resulted of one of my team to be invited to give a short presentation about asthma and her research at the Summer fest of the Brune Park School in Gosport in July 2014.</gtr:impact><gtr:outcomeId>545b6e2785b993.93006973</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC network magazine: Controlling ADAM33 gene could stop asthma</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E8B82FF3-ACF9-402D-B287-0B5847923DA9</gtr:id><gtr:impact>This was a short summary of our research outcome for the Medical Research Council (MRC) in their news section of the network magazine together with the press release by the University of Southampton in connection with our publication in The Journal of Clinical Investigation - Insight with the title: Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life in 2016.</gtr:impact><gtr:outcomeId>58c95779ac03d5.87334706</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://www.mrc.ac.uk/news/browse/controlling-adam33-gene-could-stop-asthma/</gtr:url><gtr:year>2013,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Asthma: Protein all m?gliche Ursache</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A3552BB5-DEBE-431C-9435-1F9F723B6B7B</gtr:id><gtr:impact>This was a short news report about our publication in the &amp;quot;&amp;Ouml;sterreichische &amp;Auml;rztezeitung&amp;quot; (a magazine for Austrian medical doctors) together with the press release by the University of Southampton the &amp;quot;Austria Presse Argentur&amp;quot; in connection with our publication in The Journal of Clinical Investigation - Insight with the title: Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life in 2016.</gtr:impact><gtr:outcomeId>58c95dcd4e4aa6.30594303</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.aerztezeitung.at/archiv/oeaez-2016/oeaez-1516-15082016/medizinische-kurzmeldungen-hiv-mers-adipositas-aml-asthma.html</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Summerfest at Brune Park School in Gosport 2014</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>40A6A52B-FAF5-41E8-BEAB-99D59525A26F</gtr:id><gtr:impact>Dr Lizzie Davies from my team spoke about the asthma research work being carried out at Southampton General Hospital and supported by the MRC and AAIR charity.

Some 450 pupils in Fonteyn House at Brune Park School have chosen the Asthma, Allergy and Inflammation Research Charity (AAIR) as their fund raising project for the year.</gtr:impact><gtr:outcomeId>545b6fef520154.82533149</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.aaircharity.org/category/fundraising-news/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Faculty of Medicine, University of Southampton Research Management Committee Fund 2011</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>University of Southampton</gtr:fundingOrg><gtr:id>4ED01FC6-BFB2-45D5-A414-AD0A76DCF336</gtr:id><gtr:outcomeId>mz3qQMbfT640</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>292000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Medical Research Foundation</gtr:department><gtr:description>Medical Research Foundation (MRF) and Asthma UK Research Grant 2015</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MRFAUK-2015-322</gtr:fundingRef><gtr:id>CBE681EA-6A80-4069-858B-09768624F395</gtr:id><gtr:outcomeId>56d877b8754838.59509216</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9658</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC Bridging the Gap grant 2012</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>University of Southampton</gtr:fundingOrg><gtr:id>F63CD565-37C1-494D-8923-7430C351A75A</gtr:id><gtr:outcomeId>tK5V5v6oyz5</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>106000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AAIR Charity Stephen T Holgate PhD Studentship 2014</gtr:description><gtr:end>2018-10-02</gtr:end><gtr:fundingOrg>Asthma Allergy &amp; Inflammation Research (AAIR)</gtr:fundingOrg><gtr:id>3EAEB397-4B47-4550-B75B-DB13AF4C1BDE</gtr:id><gtr:outcomeId>5457539d0268b5.19639890</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1400</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AAIR Travel Fellowship 2015</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>Asthma Allergy &amp; Inflammation Research (AAIR)</gtr:fundingOrg><gtr:id>0A4B12D2-EA53-46F7-A152-E8E9082954F9</gtr:id><gtr:outcomeId>56d82614948d00.62297305</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>23100</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AAIR Charity Research Grant 2013</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Asthma Allergy &amp; Inflammation Research (AAIR)</gtr:fundingOrg><gtr:id>C85651D3-6474-4243-9E70-F73FAC01D49A</gtr:id><gtr:outcomeId>Y22wz79ryWF</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4500</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ERS short term research training fellowship for PhD student from Salzburg Austria, 2010</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>European Respiratory Society (ERS)</gtr:fundingOrg><gtr:id>E9664188-3F40-4831-A8FF-BB9D04D51854</gtr:id><gtr:outcomeId>sbyvBZ2sibv0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>Austria, Republic of</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>OEGP-Short term fellowship 2012 for PhD student from Salzburg, Austria</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>Austrian Society of Pneumology?(?GLUT)</gtr:fundingOrg><gtr:id>E525CF76-B9B1-40B9-89BF-A2438251BD44</gtr:id><gtr:outcomeId>WCUb1MZ6skH</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>89000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NC3R grant for non-mammalian models for asthma research</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:fundingRef>NC/M001482/1</gtr:fundingRef><gtr:id>9E52A5ED-B424-4747-8003-714D9C510EF8</gtr:id><gtr:outcomeId>56d827b1a2b830.12083850</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>21000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Southampton Postgraduate Research Scholarship Fund 2010</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>University of Southampton</gtr:fundingOrg><gtr:id>7CD93C9A-4ECD-4DED-BF50-EFA0D58623CC</gtr:id><gtr:outcomeId>rm7rGGdcy4S0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>19968</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Southampton Annual Adventure in Research Grant 2011</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>University of Southampton</gtr:fundingOrg><gtr:id>1899C8EE-1C11-47D4-A12E-4A3C3AAB292D</gtr:id><gtr:outcomeId>QQ8ccQiiz7L0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wessex Medical Research Innovation Grant 2011</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>University of Southampton</gtr:fundingOrg><gtr:id>9F7A641F-3096-443F-8061-943462FDD648</gtr:id><gtr:outcomeId>Xhzb5XYttUf0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>11800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AAIR Charity Research Grant 2014</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Asthma Allergy &amp; Inflammation Research (AAIR)</gtr:fundingOrg><gtr:id>E8E8DA5A-37E9-40C7-83F3-7926D9C71A0A</gtr:id><gtr:outcomeId>54575293b929d1.59218943</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of Senate, University of Southampton</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>68B6CDDD-046F-4988-8A32-B68383F89DF4</gtr:id><gtr:impact>As member of Senate at the University of Southampton we had to vote on changes in the regulator environment for undergraduate and postgraduate students as well on new implementations to improve educational and skill levels of the University workforce. Our decisions have also impacted local communities and social services in particular related to students and change in policies.</gtr:impact><gtr:outcomeId>58c96ffe85d2d3.05803381</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>During my time I have adapted and used iodine in form of Lugol solution to stain different mouse and human tissues to enhance the radiographic contrast for Micro CT imaging</gtr:description><gtr:id>C48DB0E4-7C89-4513-A662-68C9D0408AE3</gtr:id><gtr:impact>Using this adapted method has resulted in images that show the hydroureter and hydronephrosis development in a Klf-5 mutant mouse model (PMID: 21803035). 
We also further used this method to study the role of Sox17 in pulmonary angiogenesis in a mouse model using Micro CT image analysis of whole ED18 embryonic Micro CTs In Cincinnati Children's Hospital Medical Center, Ohio, USA. Analysis of the CT scans was done in collaboration with Philipp Thurner and Nick Udell from the Bioengineering Group at the School of Engineering Science at the University of Southampton (AW Lange, HM Haitchi, A Sridharan, N Udell, P Thurner, SE. Wert, Yan Xu, JA. Whitsett. Sox17 is required for normal pulmonary vascular morphogenesis, Dev Biol. 2014 Mar 1;387(1):109-20).</gtr:impact><gtr:outcomeId>FDS33sBgDmw</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Adaptation of Iodine stain of tissue for Micro CT imaging</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://europepmc.org/abstract/MED/21803035</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Lung specific conditional transgenic ADAM33-Ecto mouse</gtr:description><gtr:id>44D1EEF2-7750-4F4B-AFD2-A530653F34BB</gtr:id><gtr:impact>This mouse will enable us to study the function of human ADAM33 in an in vivo lung model.</gtr:impact><gtr:outcomeId>KYJtANVHoNy</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ADAM33-Ecto transgenic mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Lung specific conditional transgenic ADAM33-MP mouse</gtr:description><gtr:id>DC2E8494-219E-4B69-B062-C8F25ABD2578</gtr:id><gtr:impact>This mouse will enable us to study the function of human ADAM33 in an in vivo lung model.</gtr:impact><gtr:outcomeId>G9YU1F6DB16</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ADAM33-MP transgenic mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Adam33 knock out mouse</gtr:description><gtr:id>F61F6943-330A-46B2-9BF0-D3AC903ABED0</gtr:id><gtr:impact>We did not have to generate this mouse from scratch because this mouse was regenerated from sperm which we received from the University of California San Francisco.</gtr:impact><gtr:outcomeId>LFYWDqnNZWf</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Adam33-knock out mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C8A1D8E2-BFB2-4D53-A041-74FB95E0FDDE</gtr:id><gtr:title>Soluble ADAM33 Causes Airway (P)Remodeling In Early Life And Enhances Eosinophilic Airway Inflammation And Bronchial Hyperresponsiveness</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08b5309dde4cf0034e1f18ad3741e703"><gtr:id>08b5309dde4cf0034e1f18ad3741e703</gtr:id><gtr:otherNames>Davies ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58bd88a5692ff7.39787408</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6122E7E3-56BB-4503-8228-B551BBF31577</gtr:id><gtr:title>Enzymatically Active sADAM33 Is Increased In Asthma And Causes Airway Remodelling Without Inflammation.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08b5309dde4cf0034e1f18ad3741e703"><gtr:id>08b5309dde4cf0034e1f18ad3741e703</gtr:id><gtr:otherNames>Davies ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58bd879a2a86e4.29051576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B81D2FB-B988-476F-86E9-A5691AF66905</gtr:id><gtr:title>Role of TIMP-1 in ADAM33-induced angiogenesis.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a63509e0691a803f9796956c77bb439"><gtr:id>6a63509e0691a803f9796956c77bb439</gtr:id><gtr:otherNames>Puxeddu I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d8215b530104.02052246</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D4AAD15-61C4-43EF-97FA-DC09E583E370</gtr:id><gtr:title>Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA.</gtr:title><gtr:parentPublicationTitle>Molecular therapy. Nucleic acids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91708bda9eef2fc4e2e16b649270c477"><gtr:id>91708bda9eef2fc4e2e16b649270c477</gtr:id><gtr:otherNames>Pendergraff HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5a9048755524a3.52937997</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AC43448-F6C1-43A5-A942-631B93D53794</gtr:id><gtr:title>Intersections between pulmonary development and disease.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/230b474e1f9743b675a2368b2a57298f"><gtr:id>230b474e1f9743b675a2368b2a57298f</gtr:id><gtr:otherNames>Whitsett JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>obEa5ssnFUi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC4B7736-F01E-4A19-8219-946855D38819</gtr:id><gtr:title>The asthma susceptibility gene ADAM33 promotes structural remodelling to augment airway inflammation and bronchial hyperresponsiveness.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08b5309dde4cf0034e1f18ad3741e703"><gtr:id>08b5309dde4cf0034e1f18ad3741e703</gtr:id><gtr:otherNames>Davies ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d81edda382e0.49764568</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>347F7351-4ABD-4F8B-987D-3E033F55965F</gtr:id><gtr:title>Soluble Enzymatically Active ADAM33 Initiates Airway Remodelling And Promotes Allergic Asthma In Early Life</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08b5309dde4cf0034e1f18ad3741e703"><gtr:id>08b5309dde4cf0034e1f18ad3741e703</gtr:id><gtr:otherNames>Davies ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58bd89f658d962.65154707</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8264BBF7-1E65-4B4D-A67E-AB72EB2302D3</gtr:id><gtr:title>S85 Corticosteroid-resistant neutrophilic airway inflammation and hyperresponsiveness caused by il-13</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7c36247b7e13ee42fc6b73c0673efa7"><gtr:id>a7c36247b7e13ee42fc6b73c0673efa7</gtr:id><gtr:otherNames>Davies E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa29a57973991.76939996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05B776C4-96E1-4D09-A541-E4E6268B60C7</gtr:id><gtr:title>Compartment-specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patients.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Lung cellular and molecular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6eb530f93d5cd7b496d2d734c87a6f22"><gtr:id>6eb530f93d5cd7b496d2d734c87a6f22</gtr:id><gtr:otherNames>Hoffmann J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1040-0605</gtr:issn><gtr:outcomeId>56d819d0022165.39948918</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F3CE7DC-5559-4DB1-8228-C3CAD8DBFEA7</gtr:id><gtr:title>Soluble human ADAM33 induces airway remodelling independent of inflammation.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08b5309dde4cf0034e1f18ad3741e703"><gtr:id>08b5309dde4cf0034e1f18ad3741e703</gtr:id><gtr:otherNames>Davies ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>546360558d56c0.99525556</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>549A0907-3174-4B6B-87D1-C38E7B9FA08C</gtr:id><gtr:title>Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life.</gtr:title><gtr:parentPublicationTitle>JCI insight</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08b5309dde4cf0034e1f18ad3741e703"><gtr:id>08b5309dde4cf0034e1f18ad3741e703</gtr:id><gtr:otherNames>Davies ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2379-3708</gtr:issn><gtr:outcomeId>58bd84cd0ac7e4.77220288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6158A2FC-C1C7-486A-AE2F-0491967AC666</gtr:id><gtr:title>SAM-pointed domain ETS factor mediates epithelial cell-intrinsic innate immune signaling during airway mucous metaplasia.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf333778ece12fc1375723897b6bd5b8"><gtr:id>bf333778ece12fc1375723897b6bd5b8</gtr:id><gtr:otherNames>Korfhagen TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_13560_20_23012424</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>701FBF3B-0BF2-49DB-9202-B2E3FCF3875C</gtr:id><gtr:title>S89 Soluble adam33 augments the pulmonary immune response promoting allergic airway sensitivity</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0bdab3d4ee372c4c8b471e4a1e6c2dd"><gtr:id>b0bdab3d4ee372c4c8b471e4a1e6c2dd</gtr:id><gtr:otherNames>Kelly J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>5aa29a575e8399.28914702</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B44DE504-465D-445A-84B5-0A363AA2CB93</gtr:id><gtr:title>Regulation of a disintegrin and metalloprotease-33 expression by transforming growth factor-?.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory cell and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/614499d6dfd60e0aac13fcc6156c92cd"><gtr:id>614499d6dfd60e0aac13fcc6156c92cd</gtr:id><gtr:otherNames>Yang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1044-1549</gtr:issn><gtr:outcomeId>pm_13560_20_22227561</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D95EBCA4-064F-4E73-ACC6-9070B94D39D7</gtr:id><gtr:title>Sox17 is required for normal pulmonary vascular morphogenesis.</gtr:title><gtr:parentPublicationTitle>Developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb3b2f78443c1f5977cefad503f131fc"><gtr:id>fb3b2f78443c1f5977cefad503f131fc</gtr:id><gtr:otherNames>Lange AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0012-1606</gtr:issn><gtr:outcomeId>pm_540e168e1687548b9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25BA1D68-22FB-46C2-B725-34718E2171B5</gtr:id><gtr:title>PhD thesis: Elucidating the role of ADAM33 in airway inflammation and remodelling in asthma</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b244139071ab4f10f490c7c8cacf3ad8"><gtr:id>b244139071ab4f10f490c7c8cacf3ad8</gtr:id><gtr:otherNames>Elizabeth R. Davies</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56d81c60aba993.58657144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFB9FDA7-431B-45A1-A32D-88A901A4A1E4</gtr:id><gtr:title>Airway remodelling induced by ADAM33 is reversible</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08b5309dde4cf0034e1f18ad3741e703"><gtr:id>08b5309dde4cf0034e1f18ad3741e703</gtr:id><gtr:otherNames>Davies ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>546363d38e2604.55915824</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C54DF74D-1B1B-4E65-BC1A-D59AC07BF61F</gtr:id><gtr:title>Increased Expression of p22phox Mediates Airway Hyperresponsiveness in an Experimental Model of Asthma.</gtr:title><gtr:parentPublicationTitle>Antioxidants &amp; redox signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4dafb97afc16e464f9c2a4183b872b22"><gtr:id>4dafb97afc16e464f9c2a4183b872b22</gtr:id><gtr:otherNames>Nagaraj C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1523-0864</gtr:issn><gtr:outcomeId>5a9048dccf9ea5.23694034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56EF1ABD-70F7-4DF1-BCD7-6CB04285350F</gtr:id><gtr:title>Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory cell and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08b5309dde4cf0034e1f18ad3741e703"><gtr:id>08b5309dde4cf0034e1f18ad3741e703</gtr:id><gtr:otherNames>Davies ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1044-1549</gtr:issn><gtr:outcomeId>pm_13560_20_22246864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BB1B59E-1E7E-4882-A2A8-918A84A675C0</gtr:id><gtr:title>A disintegrin and metalloprotease (ADAM) 33 protein in patients with pulmonary sarcoidosis.</gtr:title><gtr:parentPublicationTitle>Respirology (Carlton, Vic.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f606b2f60b6cbba41d19007792d4182"><gtr:id>5f606b2f60b6cbba41d19007792d4182</gtr:id><gtr:otherNames>Shaffiq A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1323-7799</gtr:issn><gtr:outcomeId>pm_13560_20_22040125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDC6DE1B-7136-41BD-B42F-A503273F4536</gtr:id><gtr:title>Resistin-like molecule-? is induced following bronchoconstriction of asthmatic airways.</gtr:title><gtr:parentPublicationTitle>Respirology (Carlton, Vic.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26e8166ed388165d7a3225ca24890017"><gtr:id>26e8166ed388165d7a3225ca24890017</gtr:id><gtr:otherNames>Grainge C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1323-7799</gtr:issn><gtr:outcomeId>pm_13560_20_22758223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77B45BA8-BEB9-4062-983F-3D79DBFF4527</gtr:id><gtr:title>Asthma und Adipositas - gef&amp;auml;hrliche Zwillinge.</gtr:title><gtr:parentPublicationTitle>Aerzte Krone, Themenheft Pneumologie</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2685e9ae4f0426e609c995ba9167c928"><gtr:id>2685e9ae4f0426e609c995ba9167c928</gtr:id><gtr:otherNames>Haitchi HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56e009d8209046.13054070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91C16991-D7D3-4BE2-86CD-B9EE55218F81</gtr:id><gtr:title>Airway epithelial transcription factor NK2 homeobox 1 inhibits mucous cell metaplasia and Th2 inflammation.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89d7a566700b631a113c361e9329c959"><gtr:id>89d7a566700b631a113c361e9329c959</gtr:id><gtr:otherNames>Maeda Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>UvH4viXskJ7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8286196-ADFC-4C3D-8F15-8367756FC020</gtr:id><gtr:title>Foxa3 induces goblet cell metaplasia and inhibits innate antiviral immunity.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7049ab5b9b59ba3f8cbf79b761c1402"><gtr:id>c7049ab5b9b59ba3f8cbf79b761c1402</gtr:id><gtr:otherNames>Chen G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>5457488f575ed6.14248937</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79DB54F8-7DB3-4CE1-AEB4-9E9058AE0247</gtr:id><gtr:title>Handbook of Proteolytic Enzymes</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/665f6076a6d9eb5b7701db28e57ff30d"><gtr:id>665f6076a6d9eb5b7701db28e57ff30d</gtr:id><gtr:otherNames>Haitchi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>978-0-12-382219-2</gtr:isbn><gtr:outcomeId>545b6a08f12328.41024519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB3A449F-2A4D-4BF6-9F98-DD091882EDF7</gtr:id><gtr:title>Asthma-Like Airway Remodelling Induced by ADAM33 Is Reversible.</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08b5309dde4cf0034e1f18ad3741e703"><gtr:id>08b5309dde4cf0034e1f18ad3741e703</gtr:id><gtr:otherNames>Davies ER</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>56d81e3405f5d2.45347050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FBBAF9C-D6CE-44A0-B1FF-A87C9C818A6D</gtr:id><gtr:title>Rhinovirus-16 induced release of IP-10 and IL-8 is augmented by Th2 cytokines in a pediatric bronchial epithelial cell model.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdf236abadd59c50f2a6319fb59a6457"><gtr:id>bdf236abadd59c50f2a6319fb59a6457</gtr:id><gtr:otherNames>Cakebread JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545748c3bd1766.39248955</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01BBB592-0B7C-49F5-B91C-8C5CB5BC49A0</gtr:id><gtr:title>CaMKII is essential for the proasthmatic effects of oxidation.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72a65512d5a2598f4d6152170ee465bc"><gtr:id>72a65512d5a2598f4d6152170ee465bc</gtr:id><gtr:otherNames>Sanders PN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>pm_13560_20_23884469</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBA0F8CD-251D-45F5-AE3F-983481B6B0A7</gtr:id><gtr:title>Asthma and obesity - dangerous twins</gtr:title><gtr:parentPublicationTitle>JATROS Pulmologie and HNO</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2685e9ae4f0426e609c995ba9167c928"><gtr:id>2685e9ae4f0426e609c995ba9167c928</gtr:id><gtr:otherNames>Haitchi HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545b6677104b98.89341459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0FAD1BA-4D22-45DF-90DE-9A7F8FB1EF0D</gtr:id><gtr:title>S128 Soluble ADAM33 Causes Airway Remodelling To Promote Allergic Airway Inflammation</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7c36247b7e13ee42fc6b73c0673efa7"><gtr:id>a7c36247b7e13ee42fc6b73c0673efa7</gtr:id><gtr:otherNames>Davies E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d81fe1dc8109.35984912</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13B77936-013F-45FF-A202-881FD2310FB4</gtr:id><gtr:title>Kruppel-like factor 5 is required for formation and differentiation of the bladder urothelium.</gtr:title><gtr:parentPublicationTitle>Developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d01f5aa0101e48c87f45ab70f32ae46c"><gtr:id>d01f5aa0101e48c87f45ab70f32ae46c</gtr:id><gtr:otherNames>Bell SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0012-1606</gtr:issn><gtr:outcomeId>U9ttEXyxvFV</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802804</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>